Phase I/II Study of Lenalidomide in Combination With Anti-PD-1 Monoclonal Antibody CT-011 in Patients With Relapsed/Refractory Multiple Myeloma
Phase of Trial: Phase I/II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; Pidilizumab (Primary)
- Indications Multiple myeloma; Plasmacytoma
- Focus Adverse reactions; Therapeutic Use
- 28 May 2019 Status changed from active, no longer recruiting to completed.
- 14 Feb 2019 Planned End Date changed from 30 Jun 2018 to 31 Dec 2019.
- 14 Feb 2019 Planned primary completion date changed from 30 Jun 2018 to 31 Dec 2019.